The purpose of this study is to evaluate the feasibility of extending a previously developed amyloid biomathematical screening methodology to support the screening of tau radiotracers during compound development. 22 tau-related PET radiotracers were investigated. For each radiotracer, in silico MLogP, , and in vitro were input into the model to predict the in vivo , , and BP under healthy control (HC), mild cognitive impaired (MCI), and Alzheimer's disease (AD) conditions. These kinetic parameters were used to simulate the time activity curves (TACs) in the target regions of HC, MCI, and AD and a reference region. Standardized uptake value ratios (SUVR) were determined from the integrated area under the TACs of the target region over the reference region within a default time window of 90-110 min. The predicted , , and BP values were compared with the clinically observed values. The TACs and SUVR distributions were also simulated with population variations and noise. Finally, the clinical usefulness index (CUI) ranking was compared with clinical comparison results. The TACs and SUVR distributions differed for tau radiotracers with lower tau selectivity. The CUI values ranged from 0.0 to 16.2, with 6 out of 9 clinically applied tau radiotracers having CUI values higher than the recommend CUI value of 3.0. The differences between the clinically observed TACs and SUVR results showed that the evaluation of the clinical usefulness of tau radiotracer based on single target binding could not fully reflect in vivo tau binding. The screening methodology requires further study to improve the accuracy of screening tau radiotracers. However, the higher CUI rankings of clinically applied tau radiotracers with higher signal-to-noise ratio supported the use of the screening methodology in radiotracer development by allowing comparison of candidate radiotracers with clinically applied radiotracers based on SUVR, with respect to binding to a single target.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314003 | PMC |
http://dx.doi.org/10.1155/2018/6287913 | DOI Listing |
Acta Neuropathol
November 2024
Department of Nuclear Medicine, LMU Hospital, Ludwig Maximilian University of Munich, Marchioninstraße 15, 81377, Munich, Germany.
Tau PET has attracted increasing interest as an imaging biomarker for 4-repeat (4R)-tauopathy progressive supranuclear palsy (PSP). However, the translation of in vitro 4R-tau binding to in vivo tau PET signals is still unclear. Therefore, we performed a translational study using a broad spectrum of advanced methodologies to investigate the sources of [F]PI-2620 tau PET signals in individuals with 4R-tauopathies, including a pilot PET autopsy study in patients.
View Article and Find Full Text PDFRadiology
November 2024
From the Department of Nuclear Medicine and PET Center, Huashan Hospital, Fudan University, Shanghai, China (J. Wu, J. Wang, Q.H., K.H., Y.G., F.X.); Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (B.L.); Department of Nuclear Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China (X.C., Z.Y., J.Z.); Department of Gerontology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, China (Q.G.); PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Conn (S.L., Y.H.H.); Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, China (T.G.); Center for Applied Statistics, Institute of Statistics and Big Data, Renmin University of China, Beijing, China (W.D.); and Shanghai Conlight Medical Laboratory, Shanghai, China (W.X., W.C., D.Y.).
Background Synaptic loss is an important factor in Alzheimer disease (AD); however, blood assays that conveniently and rapidly reflect changes in synaptic density are lacking. Purpose To correlate multiple potential synaptic blood markers with synaptic density measured using F-SynVesT-1, a fluorine 18 (F)-labeled radiotracer, brain PET and to explore the independent associations between these markers and synaptic density. Materials and Methods This prospective study included 50 cognitively unimpaired (mean age, 65.
View Article and Find Full Text PDFEur J Med Chem
January 2025
Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing, 100875, China; Center for Advanced Materials Research, Beijing Normal University at Zhuhai, Zhuhai, 519087, China. Electronic address:
The presence of aggregated Tau in the brain is a dominant pathological hallmark of Tauopathies, particularly in Alzheimer's disease (AD). Therefore, developing ligands that can specifically and sensitively bind to Tau aggregates is essential for diagnosing and monitoring therapeutic interventions. In this study, we further investigated the structural optimization of the diarylamine skeleton, which exhibited promising binding characteristics and biological properties.
View Article and Find Full Text PDFPET Clin
January 2025
Diagnostic Nuclear Medicine Division, Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, Delhi, India. Electronic address:
Neuroimaging, particularly positron emission tomography (PET), plays a crucial role in diagnosing and managing brain disorders by providing insights into diverse neuropathologies such as vascular issues, infections, inflammation, degenerative diseases, and tumors. In dementia, [18F]FDG-PET helps predict Alzheimer's disease (AD) development from mild cognitive impairment, revealing metabolic reductions in specific brain regions. PET's evolution with novel radiotracers and advanced imaging techniques addresses diagnostic challenges and enhances disease monitoring.
View Article and Find Full Text PDFPET Clin
January 2025
ToNIC, Toulouse NeuroImaging Center, UMR 1214, Université de Toulouse, INSERM, Université Paul-Sabatier, Toulouse, France; Department of Nuclear Medicine, University Hospital of Toulouse, Place du Dr Baylac, Toulouse Cedex 31059, France. Electronic address:
Since the 2000s, Nuclear Medicine has primarily used SPECT with DaTSCAN and PET with [18F]-FDG to explore movement disorders. Recent advances in PET radiotracers, such as LBT 999 for dopamine transporters and tau tracers like flortaucipir for tauopathies, are enhancing diagnostic precision. Other PET tracers target neuroinflammation, synaptic density, cholinergic function, and adenosine A2A receptors.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!